An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis ; volume:10 ; number:1-2 ; year:2019 ; pages:98-114
Molecular syndromology ; 10, Heft 1-2 (2019), 98-114
- Urheber
-
Seda, Marian
Geerlings, Maartje
Lim, Peggy
Jeyabalan-Srikaran, Jeshmi
Cichon, Ann-Christin
Scambler, Peter J.
Beales, Philip L.
Hernandez-Hernandez, Victor
Stoker, Andrew W.
Jenkins, Dagan
- DOI
-
10.1159/000491567
- URN
-
urn:nbn:de:101:1-2019030623143242142831
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Seda, Marian
- Geerlings, Maartje
- Lim, Peggy
- Jeyabalan-Srikaran, Jeshmi
- Cichon, Ann-Christin
- Scambler, Peter J.
- Beales, Philip L.
- Hernandez-Hernandez, Victor
- Stoker, Andrew W.
- Jenkins, Dagan
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Biobank for craniosynostosis and faciocraniosynostosis, rare pediatric congenital craniofacial disorders: a study protocol
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Craniofacial morphology and growth in Muenke syndrome, Saethre-Chotzen syndrome, and TCF12-related craniosynostosis
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Biobank for craniosynostosis and faciocraniosynostosis, rare pediatric congenital craniofacial disorders: a study protocol
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Craniofacial morphology and growth in Muenke syndrome, Saethre-Chotzen syndrome, and TCF12-related craniosynostosis
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Biobank for craniosynostosis and faciocraniosynostosis, rare pediatric congenital craniofacial disorders: a study protocol
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics